^
BIOMARKER:

RAD51B mutation

i
Other names: RAD51 Paralog B, DNA Repair Protein RAD51 Homolog 2, RAD51 Homolog B, RAD51L1, R51H2, RAD51 Homolog B (S. Cerevisiae), RAD51 (S. Cerevisiae)-Like 1, RAD51-Like 1 (S. Cerevisiae), RAD51-Like Protein 1, RecA-Like Protein, Rad51B
Entrez ID:
Related biomarkers:
15d
Enrollment open
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • BRCA (Breast cancer early onset) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • CHEK1 expression
|
FoundationOne® CDx
|
Trodelvy (sacituzumab govitecan-hziy) • berzosertib (M6620)
24d
P1/2, N=71, Not yet recruiting, Yonsei University | Trial completion date: Dec 2022 --> May 2023 | Initiation date: May 2021 --> Oct 2021 | Trial primary completion date: Jul 2022 --> Dec 2022
Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
|
HER-2 positive • BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • paclitaxel
30d
P2, N=28, Recruiting, Se-Hoon Lee | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • RAD51B (RAD51 Paralog B) • SLFN11 (Schlafen Family Member 11) • RAD51 (RAD51 Homolog A) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • RAD54L (DNA Repair And Recombination Protein RAD54) • BRCA (Breast cancer early onset) • RAD52 (RAD52 Homolog DNA Repair Protein) • RECQL5 (RecQ Like Helicase 5) • WRN (WRN RecQ Like Helicase) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RECQL (RecQ Like Helicase) • RECQL4( RecQ Like Helicase 4) • RPA1 (Replication Protein A1)
|
BRCA1 mutation • BRCA2 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • MRE11A mutation • RAD50 mutation • RAD54L mutation • BLM mutation • BRCA mutation • NBN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation
|
Lynparza (olaparib) • Avastin (bevacizumab)
2ms
P2, N=20, Not yet recruiting, Massachusetts General Hospital
New P2 trial
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • BAP1 (BRCA1 Associated Protein 1) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • XRCC2 (X-Ray Repair Cross Complementing 2) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin))
|
BRCA1 mutation • ATM mutation • HRD • PALB2 mutation • BAP1 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • HRD + BRCA1 mutation • MRE11A mutation • RAD50 mutation • RAD54L mutation • NBN mutation
|
Zejula (niraparib)
2ms
P2, N=30, Not yet recruiting, West Cancer Center
New P2 trial
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • FANCI (FA Complementation Group I)
|
BRCA1 mutation • ATM mutation • HRD • PALB2 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • HRD + BRCA1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation
|
Zejula (niraparib) • Jemperli (dostarlimab)
2ms
Clinical • New P2 trial
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
|
BRCA1 mutation • ATM mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • ATM positive
|
docetaxel • senaparib (IMP4297)
3ms
Clinical • New P2 trial • Combination therapy
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • RAD51B (RAD51 Paralog B) • SLFN11 (Schlafen Family Member 11) • RAD51 (RAD51 Homolog A) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • RAD54L (DNA Repair And Recombination Protein RAD54) • BRCA (Breast cancer early onset) • RAD52 (RAD52 Homolog DNA Repair Protein) • RECQL5 (RecQ Like Helicase 5) • WRN (WRN RecQ Like Helicase) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RECQL (RecQ Like Helicase) • RECQL4( RecQ Like Helicase 4) • RPA1 (Replication Protein A1)
|
BRCA1 mutation • BRCA2 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • MRE11A mutation • RAD50 mutation • RAD54L mutation • BLM mutation • BRCA mutation • NBN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation
|
Lynparza (olaparib) • Avastin (bevacizumab)
4ms
P2, N=50, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Mar 2022 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Jan 2022
Trial completion date • Trial primary completion date
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • ATM (ATM serine/threonine kinase) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
|
Lynparza (olaparib)
5ms
CtDNA can characterize the mutational feature of HRR in OC . Around 42.3% of patients with OC harbour germline or somatic HRR mutations . The expanded use of PARP inhibitors in HRR deficient tumours using a signature of HRR by ctDNA in clinical practice requires validation.
Clinical • BRCA Biomarker • PARP Biomarker
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • PALB2 (Partner and localizer of BRCA2) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54)
|
BRCA1 mutation • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • RAD54L mutation • CHEK1 mutation • RAD51 mutation • CHEK1 expression
5ms
In our EOC series the concordance of two Laboratories in the identification of clinically relevant HRR mutations on tumor is high but discrepancies in interpretation remain a challenge that needs further harmonization.
Clinical • BRCA Biomarker • PARP Biomarker
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L)
|
BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD51 mutation • CHEK1 expression
5ms
Our data suggest that detection of somatic mutations in HRR genes might contribute to identify patients who might benefit from immune checkpoint blockade therapy and PARP inhibitors . In addition, the molecular features of HRR provide new opportunities to predict the tumor response to multiple treatments . Exploring other biomarkers of HRD to predict the response to PARPi and immunotherapeutic in colon cancer is necessary.
Tumor Mutational Burden • PARP Biomarker • MSi-H Biomarker • BRCA Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • ATM (ATM serine/threonine kinase) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency) • CD8 (cluster of differentiation 8) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • IFNG (Interferon, gamma) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L)
|
BRCA2 mutation • MSI-H/dMMR • ATM mutation • HRD • CDK12 mutation • BRIP1 mutation • CHEK2 mutation • RAD51B mutation • BARD1 mutation • RAD51 mutation • CHEK1 expression
|
MSK-IMPACT
5ms
Our data suggest that detection of somatic mutations in HRR genes might contribute to identify patients who might benefit from immune checkpoint blockade therapy . In addition, the molecular features of HRD provide new opportunities to predict the tumor response to multiple treatments.
BRCA Biomarker • IO biomarker
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L)
|
BRCA1 mutation • ATM mutation • HRD • PALB2 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • HRD + BRCA1 mutation • CHEK1 expression
5ms
CtDNA can characterize the mutational feature of HRR in BC . our study contributes to the understanding of the HRR pathways and specific genetic alterations harbored by Chinese patients with BC that could potentially be developed as markers of treatment response to targeted therapeutics . Ref: Razavi P, Chang MT, Xu GT, et al .
BRCA Biomarker • PARP Biomarker • Circulating tumor DNA
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1)
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • RAD51 mutation • CHEK1 expression
5ms
Co-existence of BRAF V600E/BRCA1/2 may represent a unique subset of advanced MSS CRC that may have a better prognosis and represent an opportunity to test novel targeted therapies . Larger prospective clinical validation trials in this subset is warranted.
Clinical • MSi-H Biomarker • BRCA Biomarker
|
BRAF (B-raf proto-oncogene) • BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • MSI (Microsatellite instability) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • BRCA (Breast cancer early onset) • FANCL (FA Complementation Group L)
|
BRAF V600E • BRCA1 mutation • BRCA2 mutation • MSI-H/dMMR • BRAF V600 • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • BRCA mutation • CHEK1 expression
5ms
P1/2, N=71, Recruiting, Yonsei University | Not yet recruiting --> Recruiting | Initiation date: Dec 2020 --> May 2021
Clinical • Enrollment open • Trial initiation date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
|
HER-2 positive • BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • paclitaxel
6ms
Conversely, its position within a critical site suggests that it is refractory to secondary mutations that would restore RAD51C gene function and lead to therapy resistance. A need for a greater understanding of the relationship between mutation position and reversion potential of HR genes is underscored, as it may help predict the effectiveness of therapies in patients with HR-deficient cancers.
Clinical • Journal
|
RAD51B (RAD51 Paralog B) • RAD51 (RAD51 Homolog A) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • XRCC2 (X-Ray Repair Cross Complementing 2)
|
RAD51D mutation • RAD51C mutation • RAD51B mutation • RAD51 mutation
6ms
Our research demonstrates that tumors from HGSOC patients responding poorly to first line chemotherapy have a distinct molecular profile characterized by actionable drug targets including PARP4.
Clinical • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • RAD51B (RAD51 Paralog B) • MECOM (MDS1 And EVI1 Complex Locus) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting)
|
PD-L1 expression • BRCA2 mutation • PIK3CA mutation • PIK3CA amplification • RAD51B mutation • RAD51 mutation
|
carboplatin • paclitaxel
6ms
New P1/2 trial
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • BRCA (Breast cancer early onset) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • CHEK1 expression
|
FoundationOne® CDx
|
Trodelvy (sacituzumab govitecan-hziy) • berzosertib (M6620)
6ms
P2, N=20, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2021 --> Mar 2022
Clinical • Trial completion date • Trial primary completion date
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • BAP1 (BRCA1 Associated Protein 1) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L)
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • RAD51 mutation • CHEK1 expression
|
Lynparza (olaparib)
7ms
P2, N=30, Active, not recruiting, Massachusetts General Hospital | N=223 --> 30
Enrollment change
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1) • CDK12 (Cyclin dependent kinase 12) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • ATRX (ATRX Chromatin Remodeler) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • FANCF (FA complementation group F) • FANCM (FA Complementation Group M) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCC (FA Complementation Group C)
|
BRCA1 mutation • BRCA2 mutation • ATM mutation • ARID1A mutation • MYC amplification • CDK12 mutation • CCNE1 amplification • ATRX mutation • BRIP1 mutation • FBXW7 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • FANCM mutation • NBN mutation
|
berzosertib (M6620)
7ms
P2, N=50, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Mar 2021 --> Aug 2021
Trial primary completion date
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • ATM (ATM serine/threonine kinase) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
|
Lynparza (olaparib)
7ms
Mutations in DDR genes were present in 22% of patients with mCRC. In patients with DDR-mutated tumors, initial treatment with FOLFOX/XELOX correlated with improved OS and a numerically higher RR compared with FOLFIRI.
Clinical • Clinical data • Journal • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L)
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • RAD51 mutation • CHEK1 expression
|
oxaliplatin • irinotecan
7ms
P2, N=15, Completed, Samsung Medical Center | Recruiting --> Completed | N=28 --> 15 | Trial completion date: Sep 2021 --> Jan 2021 | Trial primary completion date: Sep 2021 --> Jan 2021
Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • ATM (ATM serine/threonine kinase) • RAD51B (RAD51 Paralog B) • RAD51 (RAD51 Homolog A) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • RAD54L (DNA Repair And Recombination Protein RAD54) • RAD52 (RAD52 Homolog DNA Repair Protein) • RECQL5 (RecQ Like Helicase 5) • WRN (WRN RecQ Like Helicase) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RECQL (RecQ Like Helicase) • RECQL4( RecQ Like Helicase 4) • RPA1 (Replication Protein A1)
|
BRCA1 mutation • BRCA2 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • MRE11A mutation • RAD50 mutation • RAD54L mutation • BLM mutation • WRN mutation • NBN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation • RPA1 mutation
|
Lynparza (olaparib)
8ms
P2, N=223, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting
Enrollment closed
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1) • CDK12 (Cyclin dependent kinase 12) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • ATRX (ATRX Chromatin Remodeler) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • FANCF (FA complementation group F) • FANCM (FA Complementation Group M) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCC (FA Complementation Group C)
|
BRCA1 mutation • BRCA2 mutation • ATM mutation • ARID1A mutation • MYC amplification • CDK12 mutation • CCNE1 amplification • ATRX mutation • BRIP1 mutation • FBXW7 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • FANCM mutation • NBN mutation
|
berzosertib (M6620)
9ms
Responses were observed in patients with alterations in the DDR genes PALB2, FANCA, BRIP1, and RAD51B. In this prospective, genomics-driven study of rucaparib in mCRPC, we found limited radiographic/PSA responses to PARP inhibition in men with alterations in ATM, CDK12, or CHEK2 However, patients with alterations in other DDR-associated genes (eg, PALB2) may benefit from PARP inhibition.
P2 data • Journal • BRCA Biomarker • PARP Biomarker
|
ATM (ATM serine/threonine kinase) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRCA (Breast cancer early onset)
|
PALB2 mutation • BRIP1 mutation • FANCA mutation • RAD51B mutation
|
Rubraca (rucaparib)
10ms
Besides, we firstly demonstrated that combination of mirin and NU7441, two inhibitors for HR and NHEJ respectively, with ionizing radiation treatment significantly enhanced DSBs, reduced clonogenic cell survival, inhibited cell proliferation, and promoted cell apoptosis in ESCC cells with DSB pathway gene amplification. These findings suggest that DSB repair pathways were significantly altered in ESCC and inhibiting DSB repair pathways might enhance the radio-sensitivity of ESCC with DSB repair up-regulation.
Journal
|
RAD51B (RAD51 Paralog B)
|
RAD51B mutation
|
NU7441
11ms
Our findings demonstrate definitively that PTEN loss does not alter the RAD51 expression, its paralogs, or the HR activity. Furthermore, deficiency in PTEN alone is not sufficient to impart enhanced sensitivity to PARPi associated with HRD. This study is the first to unequivocally demonstrate that PTEN deficiency is not linked to the RAD51 expression or the HR activity amongst primary neural and non-neural Pten-null cells, PTEN-deficient tumor cell lines, and primary PTEN-mutant GBM patient-derived tissue specimens and BTICs.
Journal • BRCA Biomarker • PARP Biomarker
|
PTEN (Phosphatase and tensin homolog) • RAD51B (RAD51 Paralog B) • RAD51 (RAD51 Homolog A) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BRCA (Breast cancer early onset)
|
PTEN mutation • PTEN loss • PTEN expression • RAD51D mutation • RAD51C mutation • RAD51B mutation • BRCA mutation • RAD51 mutation
|
Lynparza (olaparib)
11ms
No mutation was identified in RAD51, MRE11A, FAM175A, XRCC2, or MLH3. The involvement of these genes in the hereditary predisposition to cancer cannot be ruled out, although if it exists it is rare or does not seem to involve truncating variants.
Clinical • Journal
|
RAD51B (RAD51 Paralog B) • RAD51 (RAD51 Homolog A) • MRE11A (MRE11 homolog, double strand break repair nuclease) • RAD50 (RAD50 Double Strand Break Repair Protein) • BARD1 (BRCA1 Associated RING Domain 1) • FANCM (FA Complementation Group M) • PMS1 (PMS1 protein homolog 1)
|
RAD51B mutation • BARD1 mutation • MRE11A mutation • RAD50 mutation • MLH3 mutation • FANCM mutation • RAD51 mutation
11ms
Clinical • New P1/2 trial • Combination therapy • PARP Biomarker • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
|
HER-2 positive • BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • paclitaxel
over1year
The diagnosis of PEL, solid variant, was made. Next-generation sequencing analysis of the tumorous and normal tissue detected a pathogenic germline mutation of the FAM175A gene and somatic mutations in BRCA2 and RAD51B (in both sarcoma and lymphoma specimens), and INPP4B and RICTOR (in lymphoma specimen only).
Clinical • Journal • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • CD38 (CD38 Molecule) • RAD51B (RAD51 Paralog B) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)
|
BRCA2 mutation • RAD51B mutation
over1year
This is currently the largest post-PARPi study identifying genomic mechanisms of resistance to PARPis. In this setting, the activity of cediranib-olaparib varied according to the PARPi resistance mechanism.
Clinical • P2 data • Journal • BRCA Biomarker • PARP Biomarker
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • CCNE1 (Cyclin E1) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • RAD51B (RAD51 Paralog B) • SLFN11 (Schlafen Family Member 11)
|
BRCA1 mutation • BRCA2 mutation • CCNE1 amplification • RAD51B mutation
|
Lynparza (olaparib) • Recentin (cediranib)
over1year
Legal entity responsible for the study The authors. Funding Has not received any funding.
BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • MSH2 (MutS Homolog 2) • RAD51B (RAD51 Paralog B) • CHEK2 (Checkpoint kinase 2) • CDH1 (Cadherin 1)
|
BRCA2 mutation • PALB2 mutation • CHEK2 mutation • MSH2 mutation • RAD51B mutation • MLH3 mutation
almost2years
P4, N=178, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2019 --> Jun 2021
Clinical • Trial completion date • BRCA Biomarker • PARP Biomarker
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • MUC16 (Mucin 16, Cell Surface Associated) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BRCA (Breast cancer early onset) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
|
BRCA1 mutation • BRCA2 mutation • CHEK2 mutation • RAD51B mutation • BARD1 mutation • BRCA mutation
|
Lynparza (olaparib)
almost2years
P2, N=71, Recruiting, University Health Network, Toronto | Trial completion date: Jun 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Jun 2021
Clinical • Trial completion date • Trial primary completion date • BRCA Biomarker • PARP Biomarker
|
BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • PALB2 (Partner and localizer of BRCA2) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • MUC16 (Mucin 16, Cell Surface Associated) • BARD1 (BRCA1 Associated RING Domain 1) • FANCM (FA Complementation Group M) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D)
|
BRCA1 mutation • BRCA2 mutation • PALB2 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • FANCM mutation • MUC16 expression • PPM1D mutation • RAD51 mutation
|
Lynparza (olaparib)